

***Fiscal Year 2024 Department of Defense Neurofibromatosis Research Program (NFRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Neurofibromatosis Research Academy – Leadership Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT942524NFRPNFRALA</a></p>	<ul style="list-style-type: none"> <li>• <b>Academy Director</b> - must be an independent and established neurofibromatosis (NF) investigator at or above the level of Associate Professor (or equivalent) as of the full application submission deadline.</li> <li>• <b>Deputy Director</b> - must be an independent NF researcher at the level of Associate Professor (or equivalent) as of the full application submission deadline and at a different institution from the Director.</li> <li>• Both the <b>Director</b> and the <b>Deputy Director</b> are required to commit <b>a minimum of 10% effort each</b> during the first year and <b>20% each</b> in subsequent years.</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Pre-application submission is required; application submission is by invitation only.</b></li> <li>• Supports the establishment and management of a multi-institutional, interactive, virtual research academy that consists of Scholars (early-career investigators) and their Career Guides (primary mentors) from different institutions under the leadership of an Academy Director and Deputy Director to foster collaborative research and career development.</li> <li>• Must have vision and plan of how the leadership team will help Academy Scholars to advance research and promote development as next generation of NF leaders.</li> <li>• Leadership/support, network opportunities, management and communication plans for the Academy must be clearly articulated.</li> <li>• Supports visionary individuals who are established NF researchers with a strong record of mentoring and commitment to leadership.</li> <li>• Academy leadership (Director and Deputy Director) <u>must have past publication records</u> in peer-reviewed journals and past and/or present research funding.</li> <li>• Clinical trials are <u>not</u> allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$1.5 million (M)</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>5</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> August 22, 2024 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> September 12, 2024 11:59 p.m. ET</p> <p><b>Oral Presentation:</b> January 2025 5:00 p.m. ET</p>
<p><b>Clinical Trial Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT942524NFRPCTA</a></p>	<p>Investigators must be at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <li>• <b>Submission of a Letter of Intent is required prior to full application submission.</b></li> <li>• Supports phase 0, 1, or 2 clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted.</li> <li>• <b>Funding must support a clinical trial and may not be used for preclinical studies.</b></li> <li>• Scientific rationale and preliminary data are required for phase 1 and 2 clinical trial applications.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$800,000</b> for direct costs.</li> <li>• Maximum funding of <b>\$1.0M</b> for direct costs for applications including a Collaborator.</li> <li>• Indirect costs may be proposed in accordance</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 12, 2024 5:00 p.m. ET</p> <p><b>Application:</b> October 3, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
			<p>with the institution’s negotiated rate agreement.</p> <ul style="list-style-type: none"> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	
<p><b>Early Investigator Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT942524NFRPEIRA</a></p>	<ul style="list-style-type: none"> <li>Investigators must be involved in a postdoctoral training or medical residency program and possess up to 4 years continuous postdoctoral research experience.</li> <li>Investigators must have successfully defended a doctoral thesis or possess an M.D. degree and <i>commit a minimum of 50% of their effort</i> towards the project.</li> </ul>	<ul style="list-style-type: none"> <li><b>Submission of a Letter of Intent is required prior to full application submission.</b></li> <li>Supports research focused on NF for individuals in the early stages of their careers.</li> <li>Investigators must have a designated mentor who is an experienced NF researcher.</li> <li>Clinical trials are <u>not</u> allowed.</li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$200,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 12, 2024 5:00 p.m. ET</p> <p><b>Application:</b> October 3, 2024 11:59 p.m. ET</p> <p><b>Confidential Letters of Recommendation:</b> October 10, 2024 5:00 p.m. ET</p>
<p><b>Exploration – Hypothesis Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">HT942524NFRPEHDA</a></p>	<p>Investigators may be from all academic levels (or equivalent).</p>	<ul style="list-style-type: none"> <li><b>Submission of a Letter of Intent is required prior to full application submission.</b></li> <li>Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in NF research.</li> <li>Projects involving human subjects or human biological substances must be exempt under the Code of Federal Regulations, Title 32, Section 219, Part 104(d) (32 CFR 219.104[d]) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.</li> <li>Preliminary and/or published data are encouraged but not required.</li> <li>Mentorship is highly encouraged.</li> <li>Clinical trials are <u>not</u> allowed.</li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$100,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 12, 2024 5:00 p.m. ET</p> <p><b>Application:</b> October 3, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Investigator-Initiated Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">HT942524NFRPIIRA</a></p>	<p>Investigators must be at or above the level of Assistant Professor (or equivalent) and must plan to <i>commit a minimum of 10% level of effort</i> for each budget period throughout the entirety of the award.</p>	<ul style="list-style-type: none"> <li>• <b>Submission of a Letter of Intent is required prior to full application submission.</b></li> <li>• Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care.</li> <li>• <b>Optional Features:</b> Applications meeting the criteria identified in the announcement may apply for a higher level of funding for the following options: <ul style="list-style-type: none"> <li>○ Qualified Collaborator.</li> <li>○ NF Open Science Initiative.</li> </ul> </li> <li>• <b>Preliminary and/or published data are required.</b></li> <li>• Clinical trials are <u>not</u> allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$525,000</b> for direct costs.</li> <li>• Maximum funding of <b>\$575,000</b> for direct costs for applications including either an Optional Qualified Collaborator or a Data Sharing Option.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 12, 2024 5:00 p.m. ET</p> <p><b>Application:</b> October 3, 2024 11:59 p.m. ET</p>
<p><b>New Investigator Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">HT942524NFRPNIA</a></p>	<ul style="list-style-type: none"> <li>• <b>Early-Stage Investigator (ESI):</b> An independent investigator who is at or below the level of Assistant Professor (or equivalent) and able to <i>commit a minimum of 30% level of effort</i> during each budget year of their efforts toward the proposed NF research project.</li> <li>• <b>Established Investigator (EI):</b> An independent investigator who is above the level of Assistant Professor and able to <i>commit a minimum of 10% level of effort</i> during each budget year of their efforts toward the proposed NF research project.</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Submission of a Letter of Intent is required prior to full application submission.</b></li> <li>• <b>ESI:</b> Supports research conducted by promising independent investigators.</li> <li>• <b>EI:</b> Supports research conducted by independent investigators who will transition from other research fields. The investigator will bring their expertise into a career in the field of NF research.</li> <li>• Experience in NF research is allowed, but not required.</li> <li>• <b>Preliminary and/or published data are required.</b></li> <li>• <b>Must not have received a New Investigator Award previously from any program within the CDMRP.</b></li> <li>• Clinical trials are <u>not</u> allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$450,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 12, 2024 5:00 p.m. ET</p> <p><b>Application:</b> October 3, 2024 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Synergistic Idea Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">HT942524NFRPSIA</a></p>	<p>Investigators must be at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <li>• <b>Submission of a Letter of Intent is required prior to full application submission.</b></li> <li>• Supports new or existing partnerships between <u>two or three investigators</u> to address a central innovative question or problem in NF that may include high risk, provided there is a potential for significant impact.</li> <li>• Investigators are expected to demonstrate the synergistic components (i.e., leveraging disciplines, expertise, or critical resources) that will significantly advance the project such that the research outcomes as a whole will be realized rapidly and efficiently and could not otherwise be accomplished through the independent efforts of a single investigator.</li> <li>• <i>Preliminary and/or published data are required.</i></li> <li>• Synergy, Research Strategy, Personnel, and Impact are the most important review criteria.</li> <li>• Clinical trials are <u>not</u> allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$2.0M</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> <li>• The maximum period of performance is <b>3</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 12, 2024 5:00 p.m. ET</p> <p><b>Application:</b> October 3, 2024 11:59 p.m. ET</p>